Hepatitis C patients who get a fever after receiving a peginterferon alfa-2a injection have a better chance of achieving a virological response, compared with patients who do not, NIH researchers report. Researcher Dr. Yaron Rotman said the data can be used by physicians to encourage patients who have side effects to continue with the therapy because they are responding to it.

Related Summaries